Department of Ultrasound, the Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, PR China.
Department of Obstetrics and Gynecology, the Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, PR China.
Int J Hyperthermia. 2023;40(1):2233713. doi: 10.1080/02656736.2023.2233713.
Transvaginal ultrasound- and laparoscopy-guided percutaneous microwave ablation (TLPMA) is a minimally invasive alternative technique with low risk, fast recovery and few side effects. We aimed to evaluate the safety and long-term efficacy of TLPMA for treating adenomyosis.
We included 79 patients with symptomatic adenomyosis who underwent TLPMA and 44 patients with adenomyosis who received the levonorgestrel-releasing intrauterine system (LNG-IUS). We evaluated the role of laparoscopy in TLPMA as well as the short- and long-term effects of TLPMA.
The mean age of the 79 patients who underwent TLPMA was 41.8 years. There was no difference in the mean age between the TLPMA and LNG-IUS groups. Laparoscopy could help to separate pelvic adhesions, provide a wide antenna path, and observe the uterine surface and bowel movement. No major complications were found in patients who underwent TLPMA. There was a significant post-treatment reduction in both the uterine and lesion volumes ( < 0.001). After a median follow-up duration of 36 months (range: 1-60 months), the uterine and lesion volumes remained stable. Additionally, most patients remained without dysmenorrhea, which confirms the long-term efficacy of TLPMA.
TLPMA is a feasible, minimally invasive technique for the treatment of adenomyosis, which significantly decreases the uterine and lesion volumes and has a good long-term effect.
经阴道超声和腹腔镜引导下经皮微波消融(TLPMA)是一种微创替代技术,具有风险低、恢复快、副作用少等优点。我们旨在评估 TLPMA 治疗子宫腺肌病的安全性和长期疗效。
我们纳入了 79 例接受 TLPMA 治疗的有症状子宫腺肌病患者和 44 例接受左炔诺孕酮宫内节育系统(LNG-IUS)治疗的子宫腺肌病患者。我们评估了腹腔镜在 TLPMA 中的作用以及 TLPMA 的短期和长期效果。
79 例行 TLPMA 治疗的患者平均年龄为 41.8 岁。TLPMA 组和 LNG-IUS 组的平均年龄无差异。腹腔镜有助于分离盆腔粘连,提供较宽的天线路径,并观察子宫表面和肠蠕动。行 TLPMA 治疗的患者未发现重大并发症。治疗后子宫和病灶体积均显著减小(均<0.001)。中位随访 36 个月(范围:1-60 个月)后,子宫和病灶体积保持稳定。此外,大多数患者仍无痛经,这证实了 TLPMA 的长期疗效。
TLPMA 是一种治疗子宫腺肌病的可行的微创技术,可显著减小子宫和病灶体积,具有良好的长期效果。